According to a report in UK pharmacy trade journal, C+D, Pfizer will be announcing a launch date for Viagra Connect “in due course”. Ever since the Rx-to-OTC switch was approved by the MHRA in November 2017, the expectation has been that Viagra Connect would launch in spring 2018, and Pfizer remains on track to hit this target.
Pfizer has said it is “currently working closely with pharmacy retailers” to deliver its biggest ever training programme, the details of which were unveiled on Monday 12th March, including 23 regional training events and e-learning modules. The latter are available on the Viagra Connect HCP website (reserved exclusively for healthcare professionals resident in the UK).
Viagra Connect is set to retail at £19.99 for a 4-tablet pack, and £34.99 for an 8-tablet pack, but any sale will first be reliant on a pharmacist consultation to confirm erectile dysfunction and to avoid any possible interactions with other medications. Pfizer is also keenly aware of the importance of pharmacy assistants in managing conversations about ED, given they are often the first point of contact in-store.
With generic versions of Viagra now available in the US, Pfizer will be monitoring the UK rollout of Viagra Connect closely for any key learnings that it can scale up to the US market. At present, however, Pfizer has not confirmed whether or not it is currently pursuing an Rx-to-OTC switch of Viagra with the US FDA.
Whether you want to find out more about the latest innovations, benchmark the competition or simply keep abreast of new launches, Nicholas Hall’s extensive OTC New Products Tracker is an essential competitive intelligence tool that you simply must trial. Subscribers can also benefit from a newsletter highlighting the key product innovations affecting the industry. Find out more or set up your free trial today by contacting david.redford@NicholasHall.com